04 September 2019
Visiongain has launched a new pharma report ADME Toxicology Testing Market Forecast 2019-2029: By Technology (Cell Culture, OMICS Tech), By Application (Systemic Toxicity, Renal Toxicity), By Method, By Region, And Segment Forecasts
The global ADME Toxicology Testing market is poised for rapid growth between 2019 and 2029. An increasing number of drug molecules has failed in the final stages of clinical trials, resulting in precious time loss and investments in drug discovery and development. This has led to greater investments in the discovery of new technologies for toxicity testing, which is destined to strengthen the market over the next decade.
ADME toxicology tests are now conducted during the design and development of drugs to prevent any late-stage failure and to ensure a systematic assessment to prevent the potential loss of a molecule or investment. Most companies follow GLP and non-GLP testing procedures to meet regulatory standards.
With the growing need for new therapies for a number of conditions, it is likely that almost all technology segments will present profitable opportunities in the forecast period. The analysis of the processed and screened data is the most important step and must be managed precisely for the required results. Recent trends have seen the development of software and chemical libraries that can help establish the best standards and the communication of results.
The leading companies in the report include Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research Inc.; Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories International Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Cipla; and CymaBay Therapeutics.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.